Rigor Reviewed

Rigor-Reviewed Manuscript

Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.

Name: Αlpha¹ Rigor Record — Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.
Item: Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.
Rating: 59
Author: Αlpha¹

Donovan J, Duc Bang N, Dong HKT, Ho DTN, Nguyen TAT, Nguyen TTH, Lam HBN, Phung VKN, Nguyen TT, Nguyen HHH, Pham KNO, Do DAT, Nguyen TMT, Dang TMH, Nguyen HL, Nguyen VVC, Hoang TH, Tran DD, Phung KL, Ramakrishnan L, Le THN, Nguyen TTT, Wolbers M, Kestelyn E, Geskus RB, Nguyen HP, Thwaites GE

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1.5★ (Critical), 0 critical, 5 high issues for “Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1.5 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×5−2.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingEthical approvals partially met−0.25★
ReportingKey resources partially met−0.25★
CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Problems surfaced7 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed
Printed percentage does not match its own countRecomputed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Ethics/consent reporting incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Copyediting1

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is methodologically strong overall, with rigorous design, detailed statistical reporting, and transparent data sharing. Two minor reporting gaps (missing regulatory framework citation, incomplete drug source identification) and several internal inconsistencies (HR discrepancy, alpha allocation, death percentage) are present but do not undermine the core findings.

Evaluation covers all eight rigor dimensions, with sub-criteria marked not applicable for human-trial-specific items (e.g., species/strain, housing). The reviewers independently agreed on all dimension statuses, and their evidence was merged. The copyedit and verification components revealed additional internal inconsistencies that are not reflected in the dimension scores but are captured in action items.

10 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks. 1 printed percentage that does not match its own count.

5 integrity concerns flagged (0 high).

Reporting

Eight Dimensions6 pass · 2 warn

The introduction cites the 2004 Vietnam dexamethasone trial, a Cochrane meta-analysis (RR 0.75), and the LTA4H genotype discovery connecting genotypes to distinct inflammatory phenotypes and dexamethasone responsiveness. The rationale directly motivates the genotype-stratified design and the decision to randomize only CC/CT carriers while giving TT carriers open-label dexamethasone. Limitations of prior work (post-hoc analyses, observational cohorts) are acknowledged in the Discussion as a reason for the discrepancy with past findings.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The premise is well established: the modest and heterogeneous benefit of corticosteroids, the discovery of LTA4H genotype-dependent inflammatory phenotypes, and prior trial evidence are all cited and logically linked to the trial's objectives.

Evidence

direct quote[Abstract / Main, paragraph 1]

“Adjunctive corticosteroids such as dexamethasone are recommended in tuberculous meningitis treatment, despite modest and heterogeneous survival benefit.”